Pre-approval Single-patient Expanded Access for Abrocitinib (PF-04965842)

Pfizer

Status

Conditions: Severe Uncontrolled Atopic Dermatitis

Treatments: Drug: abrocitinib

Study type: Expanded Access

Funder types: Industry; Other

Identifiers

NCT05466578

B745

Details and patient eligibility

About

Provide pre-approval single patient Expanded Access (compassionate use) of abrocitinib for patients with severe uncontrolled atopic dermatitis

Full description

In Expanded Access, treating physicians are the Sponsor.

Expanded Access requests from treating physicians may be submitted at www.pfizercares.com ; availability will depend on location/country.

Sex: All

Ages: 12+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Must have severe uncontrolled atopic dermatitis refractory to other available treatments